Varicella zoster virus redux

In May 2008, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention in the USA recommended the routine administration of a live-attenuated high-potency varicella zoster vaccine to all adults over 60 years of age without specific contraindications, f...

Full description

Saved in:
Bibliographic Details
Published inHerpes Vol. 15; no. 3; p. 62
Main Author Gelb, Lawrence D
Format Journal Article
LanguageEnglish
Published England 01.01.2009
Subjects
Aged
Aged, 80 and over
Herpes Zoster - epidemiology
Herpes Zoster - prevention & control
Herpes Zoster Vaccine - administration & dosage
Herpes Zoster Vaccine - immunology
Herpesvirus 3, Human
Humans
Mass Vaccination
Middle Aged
Practice Guidelines as Topic
Online AccessGet more information

Cover

More Information
Summary:In May 2008, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention in the USA recommended the routine administration of a live-attenuated high-potency varicella zoster vaccine to all adults over 60 years of age without specific contraindications, for the prevention and attenuation of herpes zoster (HZ). Nevertheless, many physicians still consider this vaccine to be of marginal value. This is not a reasonable conclusion. This short article reviews available data.
ISSN:0969-7667